Universität zu Köln

Seeliger, Hendrik, Pozios, Ioannis, Assmann, Gerald, Zhao, Yue, Mueller, Mario H., Knoesel, Thomas, Kreis, Martin E. and Bruns, Christiane J. (2018). Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. BMC Cancer, 18. LONDON: BMC. ISSN 1471-2407

Full text not available from this repository.

Abstract

BackgroundThe relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did not show any benefit. Here, we analyze the impact of recently characterized ER isoform beta on survival in a cohort of patients with resected PDAC.MethodsEighty-four patients having undergone pancreatic resection for PDAC at a single institution were identified. Tissue microarrays were constructed of archival tumor specimens. The expression of ER beta was determined by immunohistochemistry and quantified by a system established for estrogen receptor expression in breast cancer. ER beta expression was then correlated with clinicopathological parameters, and univariate and multivariate survival analyses were performed.ResultsNuclear expression of ER beta was found in 31% of tumors. No significant correlation was found between ER beta expression and TNM status, tumor grade, age or sex. Univariate analysis revealed nodal metastasis and the expression of ER beta as factors correlating with a shorter overall survival and disease free survival. When comparing ER beta expression in patients surviving more than 24months with those who died from the tumor within 12 or 24months, respectively, a significantly lower ER beta expression was found in the long term survivors. In multivariate analysis, ER beta expression was demonstrated to be an independent predictor of shorter overall survival.ConclusionsIn resected PDAC, expression of ER beta seems to correlate with poor prognosis. These data may help to identify patients who may benefit from additional systemic therapy including selective estrogen receptor modulators.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Seeliger, Hendrik UNSPECIFIED UNSPECIFIED UNSPECIFIED Pozios, Ioannis UNSPECIFIED UNSPECIFIED UNSPECIFIED Assmann, Gerald UNSPECIFIED UNSPECIFIED UNSPECIFIED Zhao, Yue UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Mario H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knoesel, Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Kreis, Martin E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bruns, Christiane J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-168952
DOI:	10.1186/s12885-018-4973-6
Journal or Publication Title:	BMC Cancer
Volume:	18
Date:	2018
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1471-2407
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EPIDERMAL-GROWTH-FACTOR; ER-BETA; TAMOXIFEN THERAPY; STEROID-RECEPTORS; PHASE-II; ALPHA; CANCER; CELL; COLON; ACTIVATION Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/16895